Get the Stockscreener App
7.91
1.98%
-0.16
Biocryst Pharmaceuticals Inc stock is traded at $7.91, with a volume of 3.20M.
It is down -1.98% in the last 24 hours and down -5.27% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$8.07
Open:
$8.05
24h Volume:
3.20M
Relative Volume:
1.04
Market Cap:
$1.66B
Revenue:
$557.51M
Net Income/Loss:
$-35.71M
P/E Ratio:
-43.94
EPS:
-0.18
Net Cash Flow:
$15.50M
1W Performance:
-4.35%
1M Performance:
-5.27%
6M Performance:
+2.59%
1Y Performance:
+2.06%
1-Day Range:
$7.89
$8.10
1-Week Range:
$7.89
$8.315
52-Week Range:
$6.015
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.91 | 1.68B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
AQR Capital Management LLC Purchases 362,175 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Parkman Healthcare Partners LLC Has $7.50 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Exome Asset Management LLC Acquires New Stake in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $16.70 Consensus Target Price from Brokerages - MarketBeat
Boothbay Fund Management LLC Cuts Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Trexquant Investment LP Has $2.92 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by Graham Capital Management L.P. - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Northern Trust Corp - MarketBeat
BioCryst Pharmaceuticals Inc. Pullback Analyzed — Is It Time to ExitWeekly Trade Report & High Conviction Trade Alerts - beatles.ru
Is BioCryst Pharmaceuticals Inc. affected by consumer sentimentJuly 2025 Outlook & Fast Entry Momentum Alerts - 뉴스영
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge - MSN
Ieq Capital LLC Buys 93,267 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Will BioCryst Pharmaceuticals Inc. outperform its industry peersEarnings Recap Summary & Safe Entry Zone Tips - beatles.ru
Panagora Asset Management Inc. Sells 306,402 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Alkeon Capital Management LLC Buys 120,199 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Forecasting BioCryst Pharmaceuticals Inc. price range with options dataJuly 2025 Closing Moves & High Return Stock Watch Alerts - Newser
Is a relief rally coming for BioCryst Pharmaceuticals Inc. holdersJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - Newser
Understanding BioCryst Pharmaceuticals Inc.’s price movementProduct Launch & Advanced Technical Signal Analysis - Newser
Is BioCryst Pharmaceuticals Inc. forming bullish engulfing patternsJuly 2025 Market Mood & Growth Focused Entry Point Reports - خودرو بانک
Does BioCryst Pharmaceuticals Inc. stock reflect fundamentalsJuly 2025 Levels & Precise Swing Trade Alerts - خودرو بانک
Can technical indicators confirm BioCryst Pharmaceuticals Inc.’s reversalJuly 2025 Breakouts & High Yield Equity Trading Tips - Newser
BioCryst Pharmaceuticals Stock (BCRX) Opinions on Q2 Revenue Surge and Conference Insights - Quiver Quantitative
BioCryst at Cantor Global Healthcare Conference: Strategic Growth and Opportunities - Investing.com Canada
BioCryst Pharmaceuticals: A High-Growth Biotech Play with a Strong Pipeline and Strategic Financial Moves - AInvest
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 09 - MarketScreener
Walleye Capital LLC Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Order flow analysis tools used on BioCryst Pharmaceuticals Inc.2025 Year in Review & Verified Stock Trade Ideas - Newser
Can BioCryst Pharmaceuticals Inc. stock double in the next yearProfit Target & Smart Investment Allocation Insights - خودرو بانک
Is BioCryst Pharmaceuticals Inc. forming a breakout pattern2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - خودرو بانک
Will BioCryst Pharmaceuticals Inc. see short term momentum2025 Geopolitical Influence & Free Real-Time Volume Trigger Notifications - Newser
What are BioCryst Pharmaceuticals Inc.’s earnings expectationsJuly 2025 Momentum & Fast Entry Momentum Trade Alerts - خودرو بانک
Can you recover from losses in BioCryst Pharmaceuticals Inc.Chart Signals & Smart Money Movement Tracker - Newser
Published on: 2025-09-04 04:25:22 - Newser
Kodai Capital Management LP Invests $3.52 Million in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Is BioCryst Pharmaceuticals Inc. still worth holding after the dipGold Moves & Detailed Earnings Play Alerts - Newser
Best data tools to analyze BioCryst Pharmaceuticals Inc. stockWeekly Volume Report & Weekly High Conviction Ideas - Newser
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
71,400 RSUs and 36,700 Stock Options: BioCryst's Latest Employee Compensation Package Details - Stock Titan
Applying Elliott Wave Theory to BioCryst Pharmaceuticals Inc.Gap Up & Daily Profit Maximizing Trade Tips - Newser
What to do if you’re stuck in BioCryst Pharmaceuticals Inc.Earnings Risk Report & Expert Approved Trade Ideas - Newser
BioCryst Pharmaceuticals Inc. stock prediction for this weekEarnings Growth Summary & AI Driven Stock Movement Reports - Newser
How to read the order book for BioCryst Pharmaceuticals Inc.Trade Analysis Report & Daily Growth Stock Investment Tips - Newser
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
Is BioCryst Pharmaceuticals Inc. a defensive stockJuly 2025 Analyst Calls & Stock Portfolio Risk Management - خودرو بانک
Fibrodysplasia Ossificans Market to Experience Notable Growth in Forecast Span by 2032, DelveInsight Predicts | Ipsen, Regeneron Pharma, Biocryst - Barchart.com
Will BioCryst Pharmaceuticals Inc. benefit from rising consumer demandMarket Performance Report & Risk Controlled Stock Pick Alerts - خودرو بانک
How to build a custom watchlist for BioCryst Pharmaceuticals Inc.July 2025 Decliners & Expert Verified Stock Movement Alerts - Newser
Custom watchlist performance reports with BioCryst Pharmaceuticals Inc.2025 Support & Resistance & Daily Risk Controlled Trade Plans - Newser
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):